Development of a highly purified multicomponent leukocyte IFN-α product

Journal of Interferon and Cytokine Research

Volumn 21, Issue 11, 2001, Pages 913-920

  Tölö, Hannele ^a   Kauppinen, Hanna Leena ^a   Alm, Gunnar ^b   Perers, Anders ^b   Lindeberg, Enni ^a   Wahlstedt Fröberg, Virve ^a   Parkkinen, Jaakko ^a  

^a FINNISH RED CROSS BLOOD SERVICE   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; DETERGENT; DNA; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; POLYSORBATE 80; PROTEIN SUBUNIT;

ARTICLE; CONTROLLED STUDY; GEL FILTRATION; HUMAN; HUMAN CELL; IMMUNOAFFINITY CHROMATOGRAPHY; INCUBATION TIME; LEUKOCYTE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PURIFICATION; PROTEIN STABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENDAI VIRUS; STORAGE; SUPERNATANT; VIRUS INACTIVATION;

ALBUMINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FILTRATION; HUMANS; INTERFERON-ALPHA; LEUKOCYTES; POLYSORBATES; PROTEIN ISOFORMS; REPRODUCIBILITY OF RESULTS; SENDAI VIRUS;

DNA VIRUSES; SENDAI VIRUS;

EID: 0035677266     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999001753289523     Document Type: Article

References (37)

1. The human type I interferon gene cluster
2. Two non-allelic human interferon alpha genes with identical coding regions
3. Human type I interferons: Structure and function
4. Identification of nine interferon-α subtypes produced by Sendai virus-induced human peripheral blood leukocytes
5. Isolation and characterization of components of human leukocyte interferon
6. Natural human interferon-alpha 2 is O-glycosylated
7. Human leukocytes from healthy individuals produce interferons-α8b,α10a and α17b when stimulated with Sendai virus
8. Five dominating subtypes in alpha interferon from Sendai virus-stimulated human leukocytes
9. Growth-inhibitory and antiviral activity of purified leukocyte interferon
10. Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures
11. Target cell specificity of two species of human interferon-alpha produced in Escherichia coli and of hybrid molecules derived from them
12. A species of human alpha interferon that lacks the ability to boost human natural killer activity
13. Anti-HIV-1 activity of recombinant and hybrid species of interferon-alpha
14. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency
15. Production of interferon in human leukocytes from normal donors with use of Sendai virus
16. Human leukocyte interferon alpha: Structure, pharmacology and therapeutic applications
17. Specificities of therapy-induced anti-interferon-α antibodies
18. Purification and characterization of multiple components of human lymphoblastoid interferon-α
19. Interferon alpha 2b but not interferon alpha 2a detected in human genomic DNA
20. In vivo development of antibodies to interferons: An update to 1996
21. Antibodies to interferon-α in treated cancer patients: Incidence and significance
22. The biology of interferon-α and clinical significance of anti-interferon antibodies
23. Therapy of hepatitis C: Interferon alfa-n1 trials
24. Inactivation of viruses in labile blood derivatives
25. Detection of serum interferon-α by dissociation-enhanced lanthanide fluoroimmunoassay
26. Virus plaque-reduction assay for interferon: Microplaque and regular macroplaque reduction assays
27. Large-scale production of a solvent-detergent treated factor IX concentrate from human plasma
28. A rapid method for the production control of the non-ionic component in synthetic detergents
29. Highlights of the 4th meeting, October 1996
30. Structural characterisation of N-linked and O-linked oligosaccharides derived from interferon-α2b and interferon-α14c produced by Sendai virus-induced human peripheral blood leukocytes
31. Affinity chromatography to remove viruses during preparation of plasma derivatives
32. Virus validation of pH 4-treated human immunoglobulin products by the Cohn fractionation process
33. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates
34. TSE removal by filtration
35. Mechanism of virus removal by regenerated cellulose hollow fiber (BMMTM)
36. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice
37. Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon alpha (IFN-α) formulation